Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin-2
K. Spanknebel, K. Hurst-Wicker, Y. K. Cheung, C. Hesdorffer, G. DeRaffele, H. KaufmanVolume:
11
Language:
english
Pages:
1
DOI:
10.1007/bf02524054
Date:
February, 2004
File:
PDF, 148 KB
english, 2004